ZA200501582B - Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4-inhibitors. - Google Patents

Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4-inhibitors. Download PDF

Info

Publication number: ZA200501582B
Authority: ZA; South Africa
Prior art keywords: alkyl; aryl; rhinitis; substituted; mono
Prior art date: 2002-09-06

Application number

ZA200501582A

Other languages

English (en)

Inventor

Chris Rundfeldt

Hildegard Kuss

Norbert Hoefgen

Original Assignee

Elbion Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-09-06

Filing date

2005-02-22

Publication date

2005-09-09

2005-02-22 Application filed by Elbion Ag filed Critical Elbion Ag

2005-09-09 Publication of ZA200501582B publication Critical patent/ZA200501582B/en

Links

208000037916 non-allergic rhinitis Diseases 0.000 title claims description 31
239000002587 phosphodiesterase IV inhibitor Substances 0.000 title description 11
206010039083 rhinitis Diseases 0.000 claims description 16
150000001875 compounds Chemical class 0.000 claims description 13
208000024891 symptom Diseases 0.000 claims description 13
208000015181 infectious disease Diseases 0.000 claims description 8
125000002837 carbocyclic group Chemical group 0.000 claims description 6
229920006395 saturated elastomer Polymers 0.000 claims description 6
208000011580 syndromic disease Diseases 0.000 claims description 6
208000001319 vasomotor rhinitis Diseases 0.000 claims description 6
206010028735 Nasal congestion Diseases 0.000 claims description 5
XEKOWRVHYACXOJ-UHFFFAOYSA-N ethyl acetate Substances CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 5
DPHDSIQHVGSITN-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(4-fluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=CC=C(F)C=C1 DPHDSIQHVGSITN-UHFFFAOYSA-N 0.000 claims description 5
206010009137 Chronic sinusitis Diseases 0.000 claims description 4
206010020751 Hypersensitivity Diseases 0.000 claims description 4
125000000217 alkyl group Chemical group 0.000 claims description 4
208000026935 allergic disease Diseases 0.000 claims description 4
125000003118 aryl group Chemical group 0.000 claims description 4
208000027157 chronic rhinosinusitis Diseases 0.000 claims description 4
210000003979 eosinophil Anatomy 0.000 claims description 3
125000000623 heterocyclic group Chemical group 0.000 claims description 3
125000002950 monocyclic group Chemical group 0.000 claims description 3
229910052760 oxygen Inorganic materials 0.000 claims description 3
150000003839 salts Chemical class 0.000 claims description 3
229910052717 sulfur Inorganic materials 0.000 claims description 3
241000233866 Fungi Species 0.000 claims description 2
UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
230000007815 allergy Effects 0.000 claims description 2
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
229910052739 hydrogen Inorganic materials 0.000 claims description 2
239000001257 hydrogen Substances 0.000 claims description 2
125000002911 monocyclic heterocycle group Chemical group 0.000 claims description 2
244000045947 parasite Species 0.000 claims description 2
125000004585 polycyclic heterocycle group Chemical group 0.000 claims description 2
125000001424 substituent group Chemical group 0.000 claims description 2
208000035143 Bacterial infection Diseases 0.000 claims 1
208000036142 Viral infection Diseases 0.000 claims 1
208000022362 bacterial infectious disease Diseases 0.000 claims 1
244000052616 bacterial pathogen Species 0.000 claims 1
125000005842 heteroatom Chemical group 0.000 claims 1
NPWTXYMIJXTJSY-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[5-hydroxy-1-[(4-hydroxyphenyl)methyl]indol-3-yl]-2-oxoacetamide Chemical compound C1=CC(O)=CC=C1CN1C2=CC=C(O)C=C2C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)=C1 NPWTXYMIJXTJSY-UHFFFAOYSA-N 0.000 claims 1
230000003612 virological effect Effects 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 72
239000000126 substance Substances 0.000 description 25
230000010412 perfusion Effects 0.000 description 22
210000002850 nasal mucosa Anatomy 0.000 description 20
241001465754 Metazoa Species 0.000 description 18
230000000694 effects Effects 0.000 description 18
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 14
206010039085 Rhinitis allergic Diseases 0.000 description 12
201000010105 allergic rhinitis Diseases 0.000 description 12
208000035475 disorder Diseases 0.000 description 12
238000012360 testing method Methods 0.000 description 12
239000000243 solution Substances 0.000 description 11
230000008728 vascular permeability Effects 0.000 description 11
229940123932 Phosphodiesterase 4 inhibitor Drugs 0.000 description 9
241000700159 Rattus Species 0.000 description 9
206010039101 Rhinorrhoea Diseases 0.000 description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
229940092705 beclomethasone Drugs 0.000 description 8
NBMKJKDGKREAPL-DVTGEIKXSA-N beclomethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O NBMKJKDGKREAPL-DVTGEIKXSA-N 0.000 description 8
230000001684 chronic effect Effects 0.000 description 8
239000003814 drug Substances 0.000 description 8
239000012530 fluid Substances 0.000 description 8
208000010753 nasal discharge Diseases 0.000 description 8
-1 for example Chemical class 0.000 description 7
238000000692 Student's t-test Methods 0.000 description 6
230000000172 allergic effect Effects 0.000 description 6
210000004027 cell Anatomy 0.000 description 6
238000002560 therapeutic procedure Methods 0.000 description 6
MSYGAHOHLUJIKV-UHFFFAOYSA-N 3,5-dimethyl-1-(3-nitrophenyl)-1h-pyrazole-4-carboxylic acid ethyl ester Chemical compound CC1=C(C(=O)OCC)C(C)=NN1C1=CC=CC([N+]([O-])=O)=C1 MSYGAHOHLUJIKV-UHFFFAOYSA-N 0.000 description 5
102000011017 Type 4 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 description 5
108010037584 Type 4 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 description 5
208000010668 atopic eczema Diseases 0.000 description 5
230000005764 inhibitory process Effects 0.000 description 5
210000003928 nasal cavity Anatomy 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
206010061218 Inflammation Diseases 0.000 description 4
108010044467 Isoenzymes Proteins 0.000 description 4
208000006673 asthma Diseases 0.000 description 4
210000004204 blood vessel Anatomy 0.000 description 4
238000002474 experimental method Methods 0.000 description 4
230000004054 inflammatory process Effects 0.000 description 4
229960001361 ipratropium bromide Drugs 0.000 description 4
KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 4
230000007794 irritation Effects 0.000 description 4
210000001331 nose Anatomy 0.000 description 4
206010041232 sneezing Diseases 0.000 description 4
150000003431 steroids Chemical class 0.000 description 4
231100000331 toxic Toxicity 0.000 description 4
230000002588 toxic effect Effects 0.000 description 4
ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 3
ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 3
CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 3
206010014950 Eosinophilia Diseases 0.000 description 3
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
208000000592 Nasal Polyps Diseases 0.000 description 3
239000004698 Polyethylene Substances 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 3
239000000812 cholinergic antagonist Substances 0.000 description 3
239000003246 corticosteroid Substances 0.000 description 3
230000001419 dependent effect Effects 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
239000007788 liquid Substances 0.000 description 3
210000004877 mucosa Anatomy 0.000 description 3
IZNRZZVWBDWWKJ-UHFFFAOYSA-N n-hydroxy-2-(1h-indol-2-yl)-2-oxoacetamide Chemical class C1=CC=C2NC(C(=O)C(=O)NO)=CC2=C1 IZNRZZVWBDWWKJ-UHFFFAOYSA-N 0.000 description 3
230000001734 parasympathetic effect Effects 0.000 description 3
239000000825 pharmaceutical preparation Substances 0.000 description 3
229920000573 polyethylene Polymers 0.000 description 3
238000002360 preparation method Methods 0.000 description 3
230000001953 sensory effect Effects 0.000 description 3
210000002966 serum Anatomy 0.000 description 3
229940124597 therapeutic agent Drugs 0.000 description 3
239000005526 vasoconstrictor agent Substances 0.000 description 3
IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
241000894006 Bacteria Species 0.000 description 2
IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
206010030113 Oedema Diseases 0.000 description 2
229940124639 Selective inhibitor Drugs 0.000 description 2
206010047141 Vasodilatation Diseases 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
ORILYTVJVMAKLC-UHFFFAOYSA-N adamantane Chemical compound C1C(C2)CC3CC1CC2C3 ORILYTVJVMAKLC-UHFFFAOYSA-N 0.000 description 2
229940125715 antihistaminic agent Drugs 0.000 description 2
239000000739 antihistaminic agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
238000004364 calculation method Methods 0.000 description 2
YKPUWZUDDOIDPM-SOFGYWHQSA-N capsaicin Chemical compound COC1=CC(CNC(=O)CCCC\C=C\C(C)C)=CC=C1O YKPUWZUDDOIDPM-SOFGYWHQSA-N 0.000 description 2
201000009151 chronic rhinitis Diseases 0.000 description 2
208000027744 congestion Diseases 0.000 description 2
210000000795 conjunctiva Anatomy 0.000 description 2
229960001334 corticosteroids Drugs 0.000 description 2
201000010099 disease Diseases 0.000 description 2
229940079593 drug Drugs 0.000 description 2
229940126534 drug product Drugs 0.000 description 2
210000002889 endothelial cell Anatomy 0.000 description 2
230000035874 hyperreactivity Effects 0.000 description 2
230000009610 hypersensitivity Effects 0.000 description 2
230000002757 inflammatory effect Effects 0.000 description 2
208000030603 inherited susceptibility to asthma Diseases 0.000 description 2
210000004126 nerve fiber Anatomy 0.000 description 2
230000008506 pathogenesis Effects 0.000 description 2
230000007310 pathophysiology Effects 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000002035 prolonged effect Effects 0.000 description 2
238000007634 remodeling Methods 0.000 description 2
238000011160 research Methods 0.000 description 2
210000002345 respiratory system Anatomy 0.000 description 2
230000028327 secretion Effects 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
231100000027 toxicology Toxicity 0.000 description 2
210000003437 trachea Anatomy 0.000 description 2
230000024883 vasodilation Effects 0.000 description 2
230000001457 vasomotor Effects 0.000 description 2
YGWFCQYETHJKNX-UHFFFAOYSA-N 2-[(4-tert-butyl-2,6-dimethylphenyl)methyl]-4,5-dihydro-1h-imidazol-3-ium;chloride Chemical compound [Cl-].CC1=CC(C(C)(C)C)=CC(C)=C1CC1=NCC[NH2+]1 YGWFCQYETHJKNX-UHFFFAOYSA-N 0.000 description 1
SLRMQYXOBQWXCR-UHFFFAOYSA-N 2154-56-5 Chemical compound [CH2]C1=CC=CC=C1 SLRMQYXOBQWXCR-UHFFFAOYSA-N 0.000 description 1
ZOOGRGPOEVQQDX-UUOKFMHZSA-N 3',5'-cyclic GMP Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-UUOKFMHZSA-N 0.000 description 1
125000000339 4-pyridyl group Chemical group N1=C([H])C([H])=C([*])C([H])=C1[H] 0.000 description 1
239000005541 ACE inhibitor Substances 0.000 description 1
241000238876 Acari Species 0.000 description 1
208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
MBUVEWMHONZEQD-UHFFFAOYSA-N Azeptin Chemical compound C1CN(C)CCCC1N1C(=O)C2=CC=CC=C2C(CC=2C=CC(Cl)=CC=2)=N1 MBUVEWMHONZEQD-UHFFFAOYSA-N 0.000 description 1
208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
206010010725 Conjunctival irritation Diseases 0.000 description 1
206010010741 Conjunctivitis Diseases 0.000 description 1
206010010744 Conjunctivitis allergic Diseases 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
206010015866 Extravasation Diseases 0.000 description 1
206010060891 General symptom Diseases 0.000 description 1
206010053759 Growth retardation Diseases 0.000 description 1
UCHDWCPVSPXUMX-TZIWLTJVSA-N Montelukast Chemical compound CC(C)(O)C1=CC=CC=C1CC[C@H](C=1C=C(\C=C\C=2N=C3C=C(Cl)C=CC3=CC=2)C=CC=1)SCC1(CC(O)=O)CC1 UCHDWCPVSPXUMX-TZIWLTJVSA-N 0.000 description 1
206010028116 Mucosal inflammation Diseases 0.000 description 1
101000909851 Mycobacterium tuberculosis (strain ATCC 25618 / H37Rv) cAMP/cGMP dual specificity phosphodiesterase Rv0805 Proteins 0.000 description 1
206010052437 Nasal discomfort Diseases 0.000 description 1
206010028748 Nasal obstruction Diseases 0.000 description 1
101710138657 Neurotoxin Proteins 0.000 description 1
206010030111 Oedema mucosal Diseases 0.000 description 1
229930182555 Penicillin Natural products 0.000 description 1
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
102000004861 Phosphoric Diester Hydrolases Human genes 0.000 description 1
108090001050 Phosphoric Diester Hydrolases Proteins 0.000 description 1
235000014676 Phragmites communis Nutrition 0.000 description 1
208000036071 Rhinorrhea Diseases 0.000 description 1
241000700605 Viruses Species 0.000 description 1
229960001138 acetylsalicylic acid Drugs 0.000 description 1
239000002253 acid Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
230000009471 action Effects 0.000 description 1
239000013543 active substance Substances 0.000 description 1
239000000443 aerosol Substances 0.000 description 1
239000013566 allergen Substances 0.000 description 1
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 1
239000005557 antagonist Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000000844 anti-bacterial effect Effects 0.000 description 1
230000001078 anti-cholinergic effect Effects 0.000 description 1
230000000843 anti-fungal effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000000840 anti-viral effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
229960004574 azelastine Drugs 0.000 description 1
239000002876 beta blocker Substances 0.000 description 1
229940097320 beta blocking agent Drugs 0.000 description 1
229960002504 capsaicin Drugs 0.000 description 1
235000017663 capsaicin Nutrition 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940082638 cardiac stimulant phosphodiesterase inhibitors Drugs 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
230000008859 change Effects 0.000 description 1
239000002561 chemical irritant Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
235000019504 cigarettes Nutrition 0.000 description 1
239000013068 control sample Substances 0.000 description 1
125000004851 cyclopentylmethyl group Chemical group C1(CCCC1)C* 0.000 description 1
238000003745 diagnosis Methods 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
231100000673 dose–response relationship Toxicity 0.000 description 1
239000006196 drop Substances 0.000 description 1
239000000428 dust Substances 0.000 description 1
210000005069 ears Anatomy 0.000 description 1
230000002497 edematous effect Effects 0.000 description 1
YQGOJNYOYNNSMM-UHFFFAOYSA-N eosin Chemical compound [Na+].OC(=O)C1=CC=CC=C1C1=C2C=C(Br)C(=O)C(Br)=C2OC2=C(Br)C(O)=C(Br)C=C21 YQGOJNYOYNNSMM-UHFFFAOYSA-N 0.000 description 1
210000000222 eosinocyte Anatomy 0.000 description 1
230000002327 eosinophilic effect Effects 0.000 description 1
210000002409 epiglottis Anatomy 0.000 description 1
230000001667 episodic effect Effects 0.000 description 1
210000000981 epithelium Anatomy 0.000 description 1
230000036251 extravasation Effects 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
230000001408 fungistatic effect Effects 0.000 description 1
210000004907 gland Anatomy 0.000 description 1
239000011521 glass Substances 0.000 description 1
239000008187 granular material Substances 0.000 description 1
210000003714 granulocyte Anatomy 0.000 description 1
231100000001 growth retardation Toxicity 0.000 description 1
125000001188 haloalkyl group Chemical group 0.000 description 1
229910052736 halogen Inorganic materials 0.000 description 1
150000002367 halogens Chemical class 0.000 description 1
210000003128 head Anatomy 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
210000003630 histaminocyte Anatomy 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
230000002458 infectious effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
150000007529 inorganic bases Chemical class 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229960001888 ipratropium Drugs 0.000 description 1
OEXHQOGQTVQTAT-JRNQLAHRSA-N ipratropium Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 OEXHQOGQTVQTAT-JRNQLAHRSA-N 0.000 description 1
230000002427 irreversible effect Effects 0.000 description 1
125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
150000002617 leukotrienes Chemical class 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000000034 method Methods 0.000 description 1
229960005127 montelukast Drugs 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
210000003097 mucus Anatomy 0.000 description 1
QQWGSRLJEDSTDP-UHFFFAOYSA-N n-(3,5-dichloropyridin-4-yl)-2-[1-[(2,6-difluorophenyl)methyl]-5-hydroxyindol-3-yl]-2-oxoacetamide Chemical compound C1=C(C(=O)C(=O)NC=2C(=CN=CC=2Cl)Cl)C2=CC(O)=CC=C2N1CC1=C(F)C=CC=C1F QQWGSRLJEDSTDP-UHFFFAOYSA-N 0.000 description 1
OHKIBRZOBFTOOK-UHFFFAOYSA-N n-hydroxy-2-(1h-indol-3-yl)-2-oxoacetamide Chemical class C1=CC=C2C(C(=O)C(=O)NO)=CNC2=C1 OHKIBRZOBFTOOK-UHFFFAOYSA-N 0.000 description 1
125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
210000001989 nasopharynx Anatomy 0.000 description 1
230000001537 neural effect Effects 0.000 description 1
239000002581 neurotoxin Substances 0.000 description 1
231100000618 neurotoxin Toxicity 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000003448 neutrophilic effect Effects 0.000 description 1
229940127234 oral contraceptive Drugs 0.000 description 1
239000003539 oral contraceptive agent Substances 0.000 description 1
150000007530 organic bases Chemical class 0.000 description 1
VSZGPKBBMSAYNT-RRFJBIMHSA-N oseltamivir Chemical compound CCOC(=O)C1=C[C@@H](OC(CC)CC)[C@H](NC(C)=O)[C@@H](N)C1 VSZGPKBBMSAYNT-RRFJBIMHSA-N 0.000 description 1
229960003752 oseltamivir Drugs 0.000 description 1
238000012261 overproduction Methods 0.000 description 1
210000003695 paranasal sinus Anatomy 0.000 description 1
210000005037 parasympathetic nerve Anatomy 0.000 description 1
229940049954 penicillin Drugs 0.000 description 1
230000035699 permeability Effects 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
229940127557 pharmaceutical product Drugs 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
239000002571 phosphodiesterase inhibitor Substances 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000000843 powder Substances 0.000 description 1
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 description 1
229960001289 prazosin Drugs 0.000 description 1
230000002265 prevention Effects 0.000 description 1
230000008569 process Effects 0.000 description 1
230000000750 progressive effect Effects 0.000 description 1
230000000770 proinflammatory effect Effects 0.000 description 1
230000035755 proliferation Effects 0.000 description 1
125000004076 pyridyl group Chemical group 0.000 description 1
230000011514 reflex Effects 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
230000004044 response Effects 0.000 description 1
210000003491 skin Anatomy 0.000 description 1
239000000779 smoke Substances 0.000 description 1
210000002460 smooth muscle Anatomy 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
239000007921 spray Substances 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000000725 suspension Substances 0.000 description 1
230000008961 swelling Effects 0.000 description 1
238000002636 symptomatic treatment Methods 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
229960000340 thiopental sodium Drugs 0.000 description 1
AWLILQARPMWUHA-UHFFFAOYSA-M thiopental sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC([S-])=NC1=O AWLILQARPMWUHA-UHFFFAOYSA-M 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
241000712461 unidentified influenza virus Species 0.000 description 1
230000002792 vascular Effects 0.000 description 1
230000000304 vasodilatating effect Effects 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
238000010792 warming Methods 0.000 description 1
238000005303 weighing Methods 0.000 description 1
229960001095 xylometazoline hydrochloride Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
- A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Tropical Medicine & Parasitology (AREA)
Virology (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200501582A 2002-09-06 2005-02-22 Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4-inhibitors. ZA200501582B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
DE10241407A DE10241407A1 (de)	2002-09-06	2002-09-06	Behandlung nicht allergischer Rhinitis durch selektive Phosphodiesterase 4-Hemmstoffe

Publications (1)

Publication Number	Publication Date
ZA200501582B true ZA200501582B (en)	2005-09-09

Family

ID=31724458

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200501582A ZA200501582B (en)	2002-09-06	2005-02-22	Treatment of non-allergic rhinitis by means of selective phosphodiesterase-4-inhibitors.

Country Status (18)

Country	Link
US (1)	US20040116501A1 (pt)
EP (1)	EP1534272A2 (pt)
JP (1)	JP2005539058A (pt)
KR (1)	KR20050034760A (pt)
CN (1)	CN1678307A (pt)
AR (1)	AR041172A1 (pt)
AU (1)	AU2003271586A1 (pt)
BR (1)	BR0314031A (pt)
CA (1)	CA2497374A1 (pt)
DE (1)	DE10241407A1 (pt)
HR (1)	HRP20050310A2 (pt)
MX (1)	MXPA05002437A (pt)
NO (1)	NO20051468L (pt)
PL (1)	PL375494A1 (pt)
RU (1)	RU2005109939A (pt)
TW (1)	TW200404777A (pt)
WO (1)	WO2004022041A2 (pt)
ZA (1)	ZA200501582B (pt)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
SG146624A1 (en)	2003-09-11	2008-10-30	Kemia Inc	Cytokine inhibitors

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HU202108B (en) *	1986-07-30	1991-02-28	Sandoz Ag	Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
DE19818964A1 (de) *	1998-04-28	1999-11-04	Dresden Arzneimittel	Neue Hydroxyindole, deren Verwendung als Inhibitoren der Phospodiesterase 4 und Verfahren zu deren Herstellung
UA82323C2 (uk) *	2002-08-09	2008-04-10	Меда Фарма Гмбх & Ко. Кг	Нова комбінація глюкокортикоїду та pde-інгібітору для лікування респіраторних захворювань, алергічних захворювань, астми та хронічних обструктивних легеневих захворювань

2002
- 2002-09-06 DE DE10241407A patent/DE10241407A1/de not_active Withdrawn
2003
- 2003-09-03 TW TW092124366A patent/TW200404777A/zh unknown
- 2003-09-03 US US10/654,365 patent/US20040116501A1/en not_active Abandoned
- 2003-09-05 AU AU2003271586A patent/AU2003271586A1/en not_active Abandoned
- 2003-09-05 RU RU2005109939/15A patent/RU2005109939A/ru not_active Application Discontinuation
- 2003-09-05 JP JP2004533499A patent/JP2005539058A/ja active Pending
- 2003-09-05 CA CA002497374A patent/CA2497374A1/en not_active Abandoned
- 2003-09-05 HR HR20050310A patent/HRP20050310A2/xx not_active Application Discontinuation
- 2003-09-05 EP EP03753390A patent/EP1534272A2/de not_active Withdrawn
- 2003-09-05 WO PCT/EP2003/009895 patent/WO2004022041A2/de not_active Ceased
- 2003-09-05 AR ARP030103238A patent/AR041172A1/es unknown
- 2003-09-05 CN CNA038210894A patent/CN1678307A/zh active Pending
- 2003-09-05 PL PL03375494A patent/PL375494A1/xx unknown
- 2003-09-05 KR KR1020057003776A patent/KR20050034760A/ko not_active Withdrawn
- 2003-09-05 BR BR0314031-8A patent/BR0314031A/pt not_active Application Discontinuation
- 2003-09-05 MX MXPA05002437A patent/MXPA05002437A/es not_active Application Discontinuation
2005
- 2005-02-22 ZA ZA200501582A patent/ZA200501582B/en unknown
- 2005-03-21 NO NO20051468A patent/NO20051468L/no unknown

Also Published As

Publication number	Publication date
WO2004022041A2 (de)	2004-03-18
TW200404777A (en)	2004-04-01
PL375494A1 (en)	2005-11-28
AU2003271586A1 (en)	2004-03-29
AR041172A1 (es)	2005-05-04
JP2005539058A (ja)	2005-12-22
CA2497374A1 (en)	2004-03-18
MXPA05002437A (es)	2005-06-03
EP1534272A2 (de)	2005-06-01
US20040116501A1 (en)	2004-06-17
WO2004022041A3 (de)	2004-05-06
DE10241407A1 (de)	2004-03-18
BR0314031A (pt)	2005-07-05
NO20051468L (no)	2005-06-03
CN1678307A (zh)	2005-10-05
KR20050034760A (ko)	2005-04-14
HRP20050310A2 (en)	2005-06-30
RU2005109939A (ru)	2005-09-10

Publication	Publication Date	Title
JP5683719B2 (ja)	2015-03-11	ベポタスチン組成物
JP4500045B2 (ja)	2010-07-14	感冒の治療のための組成物
ES2236189T3 (es)	2005-07-16	Nueva combinacion de antihistaminicos no sedativos que contienen sustancias que influyen en la accion del leucotrieno, para el tratamiento de la rinitis/conjuntivitis.
JP6827948B2 (ja)	2021-02-10	呼吸器疾患の治療
EP4157272B1 (en)	2025-07-02	Remdesivir for the treatment of viral infections
US20100297034A1 (en)	2010-11-25	Osmolyte-containing preparation for use in case of dry mucous membranes
US20080319087A1 (en)	2008-12-25	Use of Ambroxol for the Treatment of Rhinovirus Infections
US20040116501A1 (en)	2004-06-17	Treatment of nonallergic rhinitis by selective phosphodiesterase 4 inhibitors
CN103561721A (zh)	2014-02-05	包含氟替卡松的鼻用药物配制剂
AU2013384129B2 (en)	2019-01-24	Oral suspension for treating eosinophilic esophagitis
CN115487180A (zh)	2022-12-20	一种用于治疗变应性鼻炎的药物组合物
CN113893220A (zh)	2022-01-07	鼻粘膜给药剂型和其应用
CN1897952B (zh)	2010-12-08	中性白细胞增多抑制剂
CN101631538A (zh)	2010-01-20	用于治疗慢性阻塞性肺病的药物
HK1193756A (en)	2014-10-03	Nasal pharmaceutical formulation